Avita Medical
From Wikipedia, the free encyclopedia
(Redirected from Clinical Cell Culture)
 |
This article has multiple issues. Please help improve it or discuss these issues on the talk page.
|
| Type | Public company (ASX: AVH) |
|---|---|
| Industry | Regenerative medicine |
| Founded | 1993 |
| Founder(s) | Fiona Wood |
| Headquarters | Perth, Western Australia Cambridge, United Kingdom Woburn, Massachusetts, USA |
| Area served | Global |
| Key people | William F. Dolphin, CEO |
| Products | Artificial skin |
| Website | avitamedical.com |
Avita Medical (ASX: AVH) develops spray-on skin processes to treat skin trauma, including burns. They market their artificial skin products under the names CellSpray and ReCell.[1] According to Avita, ReCell has been approved for marketing and sale in Europe, Canada and Australia.[2]
Originally named "Clinical Cell Culture" (ASX: C3), the company restructured under the name "Avita Medical" in June 2008 with a new CEO, William Dolphin.
[edit] US Government grant
In 2009 the United States Armed Forces Institute of Regenerative Medicine provided Avita with a US$1.45 million grant to hasten the approval of the ReCell kit with the U.S. Food and Drug Administration.[3]
[edit] References
- ^ "Spray-on skin speeds up healing burns" Australian Broadcasting Corporation November 23, 2009.
- ^ "Avita Medical - Recell" Accessed February 18, 2011.
- ^ "Avita boosted by US affirmation" The Age May 27, 2009.
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
